PRESS RELEASE to present expanded data on ALADIN and new data on ADVANCE expand...

Breadth of ALADIN data to reinforce results in expanded scans across multiple centers Important research will highlight a potential use case for’s deep learning, artificial intelligence algorithms beyond acute ischemic stroke.


Stryker’s Trevo™ Retriever becomes first and only device indicated for a...

Kalamazoo, Michigan, USA – Following the expanded indication in the United States by the Food and Drug Administration (FDA) in February, Stryker’s Trevo Retriever has received CE marking as a front-line treatment for patients experiencing acute ischemic stroke up to 24 hours from symptom onset, increasing the treatment window by 18 hours.


Medtronic Receives FDA Clearance for Riptide(TM) Aspiration System

New System Expands Neurovascular Product Portfolio for the Treatment of Acute Ischemic Stroke.


The world’s first software that offers product and patient spec...

Montpellier Fr. - Sim&Cure, a medical technology company focuses on the development and commercialization of a simulation software, Sim&Size®, for devices treating patients with cerebral aneurysm. The simulation can be done during the intervention or pre-intervention.


Microvention celebrates grand opening of new worldwide innovation center...

ALISO VIEJO, CA - MicroVention, a wholly owned  subsidiary of Terumo Corporation and a global neurovascular company, today announced that the Grand Opening of its New Innovation Center was held on Monday, September 25. The opening of the new facility, located in the heart of the Summit Office Campus, also signifies the Company's official return to Aliso Viejo: MicroVention was founded there in 1997, originally occupying buildings very close to the new location and is also commemorating their 20 year anniversary as a Company.


Johnson & Johnson Medical Devices Companies announces new neurovascular...

Colorado Springs, Co. – Johnson & Johnson Medical Devices Companies* today introduced CERENOVUS,** its new neurovascular business, at the Society of NeuroInterventional Surgery (SNIS) 14th Annual Meeting. CERENOVUS, a name derived from the Latin words for ‘new’ and ‘brain’, will focus on delivering innovative therapies for hemorrhagic and ischemic stroke patients.


phenox as Silver Sponsor of LINNC 2017

On June 13-15, the 20th “Live International Neuroradiology and Neurosurgery Course” took place. Specialists of neuroradiology met at the Carrousel du Louvre in Paris, to discuss live cases which were presented from all over the world. phenox has sponsored the LINNC for years. This year was the first time phenox was a silver sponsor of the meeting and was present with a booth, a training area as well as its own symposium.


DAWN™ Trial results demonstrate a 73% reduction in disability in stroke...

Kalamazoo, Michigan, USA – Results from the DAWN Trial were presented today at the European Stroke Organisation Conference (ESOC), providing compelling evidence that more patients suffering ischemic stroke may benefit from endovascular treatment. While previous randomized clinical trials have proven the benefit of stent retrievers within six hours of stroke onset, the DAWN Trial is the first to evaluate the late‐window and wake‐up stroke patient population.